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Breast cancerWhile the majority of RNA transcripts from protein-encoding genes in the human genome are subject to
physiological splicing, pathological splicing is increasingly reported in cancer tissue. Previously, we identiﬁed
>90 different splice variants of Chk2, a gene encoding a serine/threonine kinase propagating the DNA
damage signal by phosphorylating and activating several downstream substrates like p53, Cdc25A, and
Cdc25C involved in cell cycle arrest and apoptosis. While alternative splice forms of other genes have been
reported to exert a dominant-negative effect on the wild-type molecules, the function of Chk2 splice protein
variants is still unclear. Here we evaluated the function of four Chk2 splice proteins for which mRNA splice
variants were identiﬁed in human breast carcinomas. These splice variants were stably expressed as nuclear
proteins. Two splice forms (Chk2Δ4 and Chk2del(2-3)) expressed kinase activity while variants Chk2Δ11
and Chk2isoI were essentially kinase inactive. Independent of intrinsic kinase activity, each splice variant
impaired wild-type Chk2 activity through heterodimerization. Based on our ﬁndings, we suggest alternative
splicing as a possible novel mechanism for repression of the Chk2 wild-type function.Chk2 wild-type; FHA domain,
aumeni syndrome; RF, reading
ppressor gene
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Recent ﬁndings have proposed 60–80% of human genes to be
subject to alternative splicing [1,2], a molecular mechanism providing
protein diversity and suggested to regulate gene functions and activ-
ities. While splicing is a normal physiological event subject to regu-
latory factors [1,3], dysregulated splicing has been linked to various
diseases including cancer [3–8]. In cancer cells, aberrant splicing may
act oncogenic through inactivation of tumor suppressors, or, alterna-
tively, by gain of function of novel proteins with tumorigenic activity
[6]. For instance, it is well documented that isoforms of Kruppel-like
factor 6 (KLF6), a transcription factor acting as a tumor suppressor,
may antagonize the wild-type gene function [9].
Chk2 (checkpoint kinase 2) is a tumor suppressor and plays a key
role in the cellular response to DNA damage. Activated ATM phos-
phorylates Chk2 at T68 located in the SQ/TQ domain [10], and
subsequently, the SQ/TQ binds to the FHA domain of a second Chk2
molecule forming a dimer [11]. Dimerization promotes multipleautophosphorylation events including T383, T387, and S516 within
the kinase domain [12,13]. Activated Chk2, which might persist in
dimers or dissociate to monomers, then propagates the DNA damage
response signal by activating downstream targets such as p53,
Cdc25A, and Cdc25C [14–19].
Previously, we revealed >90 different splice variants of Chk2
mRNA in breast cancer tissue [20], all expressed concomitantly with
the Chk2 wild-type transcript. Alternatively spliced Chk2 forms were
found also in non-tumor tissue samples, but the breast cancers
harbored a higher number of splice forms in a more complex and
heterogeneous splicing pattern. While functional analysis of six splice
variants revealed lack of kinase activity among four splice forms and
one was found to localize pan-cellularly [20], the biological role of
Chk2 splicing still remains poorly understood.
To study the function of Chk2 splice variant proteins and their
potential interference with Chk2 wild-type function, four Chk2mRNA
splice variants observed in human breast carcinomas [20] were
selected based on their lack of sequences known to be essential for
Chk2 function (Fig. 1). Most of the Chk2 mRNA splice variants
originally detected presented similar exon losses [20], thus, the splice
forms studied in this report were chosen to represent the majority of
the total Chk2 splice repertoire observed in breast cancer biopsies.
Notably, previous work from our group has shown defects in the
Chk2-p53 pathway to be associated with resistance to anthracycline/
mitomycin therapy [21–23]. Hypothesizing splice variants to express
Fig. 1. Schematic presentation of Chk2wt and splice variants. (A) The Chk2 protein contains 543 amino acids and has three distinct functional domains; SQ/TQ cluster domain (SCD)
harboring the T68 residue phosphorylated by ATM, fork-head-associated (FHA) domain which is a phosphopeptide recognition motif, and kinase domain including the T loop. (B)
Overview of the 14 coding exons in Chk2. The regions missing in the four splice variants are indicated in red bars and white gaps.
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variants expressed in tumors resistant to doxorubicin therapy despite
harboring wild-type Chk2 and TP53.
Two of the four splice variants, Chk2iosI (GenBank accession
number AY551295) and Chk2del(2-3) (GenBank accession number
AY551303) were reported in our previous publication [20], while the
other two, Chk2Δ4 (GenBank accession number not yet available) and
Chk2Δ11 (GenBank accession number not yet available), were
identiﬁed from the same material but have not been described
previously. We here present data regarding the stability, subcellular
localization, dimerization ability, and kinase activity of these splice
variants, as well as their impact on the kinase activity of wild-type
Chk2. All splice forms encoded stable Chk2 protein variants which
localized to the nucleus and formed heterodimers with wild-type
Chk2. Most importantly, they signiﬁcantly reduced Chk2 kinase
activity when co-expressed with the wild-type protein, thus revealing
a dominant-negative effect on Chk2 wild-type.
2. Materials and methods
2.1. Plasmid construction
Among the 90 different splice variants of Chk2 observed by Staalesen
et al. in primary breast cancer tumors [20], Chk2isoI, Chk2del(2-3),Table 1
Characteristics of the analyzed Chk2 protein splice variants.
Chk2 protein variant Chk2isoI Chk2del(2-3)
Missing basepairs 223–1176 320–592
Reading frame after splice In RF In RF
Conserved domains SCD SCD, kinase
Molecular mass (kDa) including V5 tag 32.4 59.6
Localization Nuclear Nuclear
Km (µM) KD 0.87
Vmax (pM/min/mg lysate) KD 9.84
Vmax/Km 11.3
Abbreviations: RF, reading frame; SCD, SQ/TQ cluster domain; FHA, fork-head associated dChk2Δ4 and Chk2Δ11were selected. The Chk2Δ4 splice form analyzed in
this work (GenBank accession number not yet available) should not be
confused with Chk2del4 (GenBank accession number AY551302)
reported in our previous work [20]. Detailed characteristics of the
analyzed Chk2 splice variants are provided in Fig. 1 and Table 1. The PCR
products of Chk2 wild-type and splice forms were TA-cloned into
the expression vectors pcDNA3.1/V5-His TOPO and pcDNA4/HisMax
TOPO (Invitrogen, CA, USA), providing respectively C-terminal V5- and
N-terminal Xpress tags. Primers for PCR and sequencing are listed in
Table 2. The resulting constructs were named Xpress-Chk2wt, Xpress-
Chk2Δ4, Xpress-Chk2Δ11, Xpress-Chk2del(2-3), Xpress-Chk2isoI, Chk2wt-
V5, Chk2Δ4-V5, Chk2Δ11-V5, Chk2del(2-3)-V5, and Chk2isoI-V5.
2.2. Cell culture
HCT116 (Chk2−/−) cells, from which the Chk2 gene has been
deleted by homologous recombination [24], and the parental cell line
HCT116 were both kindly provided by Dr. F. Bunz (Johns Hopkins
University). U-2 OS cells expressing only low levels of endogenous
Chk2 [19,21], were purchased from ATCC. All three cell lines were
cultured in McCoys 5A supplemented with 10% FBS. The MCF-7 cell
line was routinely maintained in RPMI-1640 supplemented with 10%
FBS and 2 mM L-glutamine. Transfection was performed using Fugene
6 (Roche, Mannheim, Germany) and Lipofectamine 2000 (Invitrogen)Chk2Δ4 Chk2Δ11 Chk2wt
593–619 1260–1292
In RF In RF






omain; KD, kinase dead.
Table 2
Primers for PCR and sequencing.
Primer Sequence Annealing temperature
Primers for PCR
Chk2 V5 S GTGATGTCTCGGGAGTCGGAT G 65 °C
Chk2 V5 AS CAACACAGCAGCACACACAGC 65 °C
Chk2 Xpress S ATGTCTCGGGAGTCGGATGTTG 65 °C
Chk2 Xpress AS TCACAACACAGCAGCACACAC 65 °C
Primers for sequencing
T7 TAATACGACTCACTATAGGG 56 °C
BGH-R CCTCGACTGTGCCTTCTA 56 °C
Chk2 AS seq GGGGTTCCACATAAGGTTCTC 65 °C
Fig. 2. Stability of Chk2wt and splice variants. Forty eight hours post-transfection of
HCT116 (Chk2−/−) cells with V5-tagged Chk2 constructs, cycloheximide was added to a
ﬁnal concentration of 50 ug/ml. Cells were harvested and lysed after 0, 2, 4, and 7 h
followed by SDS-PAGE and western blot analysis using anti-V5 and anti-β-tubulin. The
protein levels were quantiﬁed using Fujiﬁlm IR LAS 1000 and Image Gauge 3.45 and
normalized to β-tubulin levels. The experiment was repeated four times. Filled circle,
Chk2isoI-V5; open circle, Chk2del(2-3)-V5; ﬁlled triangle, Chk2wt; open triangle,
Chk2Δ4-V5; ﬁlled square, Chk2Δ11-V5.
388 E.O. Berge et al. / Biochimica et Biophysica Acta 1803 (2010) 386–395according to the manufacturer's instruction. For induction of DNA
damage, the cells were treated with 50 ng doxorubicin/ml.
2.3. Immunoﬂuorescence
Immunoﬂuorescence was performed as described previously [25]
using anti-V5 (1:1000) as primary antibody and Texas red conjugated
goat anti-mouse secondary antibody (1:50).
2.4. Determination of protein stability
Forty eight hours post-transfection, cycloheximide was added to a
ﬁnal concentration of 50 µg/ml. After 0, 2, 4, and 7 h, the cells were
harvested and lysed in IPH buffer [26] followed by SDS-PAGE and
western blot analysis using anti-V5 and anti-β-tubulin (loading
control). The protein levels were quantiﬁed using Fujiﬁlm IR LAS
1000 and Image Gauge 3.45 and normalized to β-tubulin levels.
2.5. Western blot analysis and immunoprecipitation
SDS-PAGE and Western blots were performed as previously
described [27]. The following antibodies were used: anti-V5 and
Xpress (Invitrogen), anti-β-tubulin (Sigma, MO, USA), phospho-Chk2
(Thr 68) and anti-Chk2 (1C12) (Cell Signalling, MA, USA), HRP-
conjugated 2 antibodies anti-mouse and anti-rabbit (GE Healthcare,
Little Chalfont Buckinghamshire, UK), and anti-mouse IgG1 and IgG2A
(SouthernBiotech, Al, USA). Immunoprecipitation was performed as
described by Starheim et al. [26].
2.6. The stability of the interaction between Chk2wt and Chk2 splice
variants
After immunoprecipitation, the beads were divided into four equal
aliquots and washed with 1x PBS containing 0.1% Triton X-100 and
respectively 0, 0.3, 0.6, and 1.0 M NaCl. Following SDS-PAGE and
western blot analysis, speciﬁc protein bands were quantiﬁed using
Fujiﬁlm IR LAS 1000 and Image Gauge 3.45. The amount of protein in
the sample washed without salt was set to 100%, and the amount of
proteins in the samples washed with increasing concentration of NaCl
was calculated relative to this (standard).
2.7. Kinase assay
Twenty four hours post-transfection, doxorubicin (Nycomed Phar-
ma, Asker, Norway) was added to a ﬁnal concentration of 50 ng/ml.
After incubation for 24 h, in vitro Chk2 kinase assay was performed
as described by Falck et al. [14,28] using equal amounts of immunopre-
sipitated protein kinase (anti-Xpress) and 0–10 µg GST-Cdc25C(200–256)
as substrate. The steady-state enzyme kinetic parameters were
calculated by nonlinear regression analysis using the SigmaPlot
Technical Graphing Software (SPSS Inc.) and the Michaelis–Menten
equation.3. Results
3.1. Chk2 splice forms encode stable protein variants with nuclear
localization
A schematic presentation of the Chk2 splice variants analyzed in
this work is presented in Fig. 1. Due to limited amount of tumor tissue
available, the splice forms could not be analyzed as endogenous
proteins. Thus, plasmid constructs encoding Chk2 wild-type and
splice forms were made for exogenous expression. For these studies,
we used HCT116 (Chk2−/−) cancer cells that do not express
endogenous Chk2, thereby providing an optimal system for studying
Chk2 splice forms. We ﬁrst tested the expression of Chk2wt (Chk2
wild-type expressed from the Chk2wt construct as described in
Section 2) and each of the splice variants in HCT116 (Chk2−/−) cells
following transfection of V5-tagged constructs of Chk2wt, Chk2isoI,
Chk2del(2-3), Chk2Δ4, and Chk2Δ11. Expressed V5-tagged Chk2
proteins with molecular mass similar to the theoretical sizes of the
Chk2 splice variant proteins (Table 1) were detected by SDS-PAGE
and western blot of cell lysates (not shown). Similar results were
obtained using the breast cancer cell line MCF-7. These experiments
demonstrate that the splice variants Chk2iso1, Chk2del(2-3),
Chk2Δ4, and Chk2Δ11 encode proteins that can be stably expressed
in human cells.
In order to estimate the half-lives of the Chk2 splice variants,
HCT116 (Chk2−/−) cells were transfected with Chk2wt-V5, Chk2Δ4-
V5, Chk2Δ11-V5, Chk2del(2-3)-V5, or Chk2isoI-V5 plasmids. Forty
eight hours after transfection, the cells were treated with 50 ug/ml
cyclohexamide to inhibit protein synthesis. The levels of the different
Chk2 variants were determined by western blot analysis over a 7 h
period (Fig. 2). The half-lives of Chk2isoI-V5, Chk2Δ11-V5, and
Chk2del(2-3)-V5 were either similar or slightly shorter than that of
Chk2wt. Surprisingly, the Chk2Δ4-V5 splice (half-life >7 h) appeared
to be signiﬁcantly more stable than Chk2wt. Taken together, these
results imply that deletion of the FHA (fork-head associated) domain
(Chk2del(2-3)) or removal of the FHA domain combinedwith a major
part of the kinase domain (Chk2isoI) does not destabilize the resulting
proteins signiﬁcantly. Likewise, the removal of a twelve amino acid
long fragment (Chk2Δ11) in the kinase domain does not affect the
protein stability compared to Chk2wt. On the other hand, elimination
of eight amino acids between the FHA and the kinase domains
(Chk2Δ4) may generate a more compact structure compared to
Chk2wt, consequently reducing molecular ﬂexibility and access for
proteases.
389E.O. Berge et al. / Biochimica et Biophysica Acta 1803 (2010) 386–395Since the biological function of Chk2 is closely linked to its nuclear
localization [29], it was important to determine the subcellular
localization of the different Chk2 splice variants. Immunoﬂuorescence
staining of V5-tagged Chk2 protein variants expressed in HCT116
(Chk2−/−) cells 48 h post-transfection revealed that similar to
Chk2wt, all four Chk2 variants were exclusively located in the nucleus
(Fig. 3). The same observations were made using the breast cancer
cell line MCF-7 (data not shown). This is in agreement with the
retention of the monopartate nuclear localization signal (PSTSRKRPR,
aa 515–522) in their C-terminal [29]. For Chk2isoI and Chk2del(2-3),
the observation of nuclear localization conﬁrms the ﬁndings in
our previous work [20]. Each control was negative with respect to
unspeciﬁc ﬂuorescence staining.Fig. 3. Analysis of subcellular localization by immunoﬂuoresence. Forty eight hours after t
labeled with anti-V5 and thereafter with Texas red conjugated goat anti-mouse secondary
(F) Chk2Δ4. Each control was negative with respect to unspeciﬁc ﬂuorescence staining, and t
right: overlay.3.2. The FHA domain in Chk2 is not required for T68 phosphorylation by
ATM
In response to DNA damage, ATM phosphorylates Chk2 at T68
located within the SQ/TQ cluster domain (SCD) [10]. This is most
likely the priming event for subsequent autophosphorylation of other
sites within Chk2, resulting in full activation of the Chk2 kinase
[13,30]. As shown in Fig. 1, T68 is present in all Chk2 protein variants
studied; thus, each splice variant can potentially become phosphor-
ylated at this position. In order to test for DNA damage induced T68
phosphorylation in the Chk2 splice forms, Xpress-tagged Chk2wt and
splice variants were expressed in U2-OS cells and treated with or
without doxorubicin. This cell line was chosen as it expresses only lowransfection with V5-tagged Chk2 construct, HCT116 (Chk2−/−) cells were ﬁxed and
antibody. (A) Vector, (B) Chk2wt, (C) Chk2del(2-3), (D) Chk2Δ11, (E) Chk2isoI, and
hree independent experiments were performed. Left: Dapi, centre: anti-V5 (Texas Red),
390 E.O. Berge et al. / Biochimica et Biophysica Acta 1803 (2010) 386–395levels of endogenous Chk2, and has been used in several studies
analyzing Chk2 kinase activity. Fig. 4A and B shows the immunoblots
using an antibody recognizing phosphorylated T68 of Chk2 protein
variants immunoprecipitated with anti-Xpress. In the absence of
doxorubicin (Fig. 4A), Chk2wt was strongly phosphorylated on T68,
most likely due to overexpression as indicated by others [31]. Chk2del
(2-3), Chk2Δ4, and Chk2Δ11 were phosphorylated to a lesser extent.
In doxorubicin-exposed cells (Fig. 4B), the level of T68 phosphory-
lation in Chk2wt and Chk2Δ4 remained unchanged, while an increase
was observed for Chk2Δ11 and Chk2del(2-3). In the case of Chk2isoI,
T68 was not phosphorylated, neither with, nor without, doxorubicin
treatment. These data suggest that ATM can phosphorylate the Chk2
splice proteins Chk2del(2-3) and Chk2Δ11, even though the former
lacks the FHA domain. In contrast to the work performed by Lee et al.
[12], our ﬁndings suggest the FHA domain to be dispensable for ATM-
mediated phosphorylation of Chk2 at T68, a ﬁnding supported by
previous studies [31].
3.3. Chk2wt and splice variants form heterodimers
Chk2 activation depends on a series of steps in vivo, one of these is
the formation of homodimers. Since all four splice variants studied
here were expressed concomitantly with Chk2 wild-type in the
tumors [20] and located in the nucleus, it was important to test
whether or not the splice variants formed heterodimers with Chk2wt,
potentially interfering with its biological function. To this end, we
investigated heterodimerization by co-transfecting Xpress-tagged
Chk2wt with V5-tagged Chk2isoI, Chk2del(2-3), Chk2Δ4, or Chk2Δ11
into HCT116 (Chk2−/−) cells followed by anti-V5 immunoprecipi-
tation and western blot analysis using anti-Xpress. The resultsFig. 4. Phosphorylation of T68 and kinase activity of Chk2wt and splice variants. U2-OS cell
Chk2wt (WT), Chk2isoI (isoI), Chk2Δ11 (Δ11), Chk2del(2-3) (del(2-3)), and Chk2Δ4 (Δ4)
Xpress. (A) SDS-PAGE and western blot analysis using phospho-Chk2 (T68) antibody of mo
presence of GST-Cdc25C(200–256) and γ-[32P]-ATP for samples treated without or (D) with
variants, the mock or (F) doxorubicin treated samples were immunoblotted using anti-Xprpresented in Fig. 5A demonstrate that Chk2isoI, Chk2del(2-3),
Chk2Δ4, and Chk2Δ11 all formed stable heterodimers with Chk2wt.
The same dimerization pattern was obtained using anti-Xpress for
immunoprecipitation and anti-V5 in the immunoblot (data not
shown). These heterodimers were formed in spite of absence in the
splice variants of relative large fragments that are integral parts of the
full length protein (Fig. 1). Noteworthy, Chk2wt formed heterodimers
with Chk2isoI and Chk2del(2-3), both lacking the FHA domain
generally considered to be required for dimerization [11]. The
dimerization experiment was ﬁrst repeated using the parental cell
line HCT116 expressing endogenous Chk2 transfected with tagged
splice forms and anti-Chk2 (1C12 cell signalling) for western blot
analysis, relying totally on the size differences for separation since a
Chk2 antibody that could discriminate between wt and splice forms is
not available. However, no binding of endogenous Chk2 to the splice
forms was observed, most likely due to a too low expression level of
endogenous wild-type Chk2. Thus, to provide sufﬁciently high
expression level of Chk2, we co-transfected untagged Chk2wt with
tagged splice variants, and heterodimerization between the splice
forms Chk2isoI, Chk2Δ4, Chk2Δ11 and Chk2wt were conﬁrmed
(Fig. 5B). In the case of Chk2del(2-3), the migration of this splice
form and untagged Chk2wt were too similar to be separated (lane 4).
Thus, no information on Chk2wt-Chk2del(2-3) heterodimerization
could be obtained by this method.
3.4. The FHA domain is not required for Chk2 dimerization
The SCD was conserved in all the four splice variants analyzed for
interaction with Chk2wt in this work (Fig. 1). The ﬁnding that the
Chk2 variants could form heterodimers with Chk2wt (containing boths transfected with Xpress-tagged constructs encoding the vector pcDNA4/HisMax (–),
were mock or doxorubicin treated for 24 h followed by extraction with beads and anti-
ck and (B) doxorubicin treated samples. (C) In vitro kinase assay was performed in the
doxorubicin. (E) To conﬁrm the presence of equal levels of the different Chk2 protein
ess.
Fig. 5. Interaction between Chk2wt and splice variants. (A) Xpress-tagged Chk2wt
was co-expressed with four different Chk2 splice variants tagged with V5 in HCT116
(Chk2−/−) cells. The lysates were incubated with anti-V5 and beads followed by
western blot analysis using anti-Xpress. (B) Performed as in A except that HCT116 cells
were transfected with untagged Chk2wt and tagged Chk2 splice forms, and anti-Chk2
was used for western blot analysis. (C) The stability of the heterodimers was tested by
washing the immunoprecipitates with 0–1 M NaCl. From the western blot analysis,
speciﬁc protein bands were quantiﬁed using Fujiﬁlm IR LAS 1000 and Image Gauge
3.45. The amount of proteins in the samples washed with increasing concentration of
NaCl was calculated relative to the sample washed without salt (standard). The
experiment was repeated four times. Filled circle, Xpress-Chk2wt/Chk2wt-V5 dimer;
open circle, Xpress-Chk2wt/Chk2Δ11-V5 dimer; ﬁlled triangle, Xpress-Chk2wt/
Chk2del(2-3)-V5 dimer; open triangle, Xpress-Chk2wt/Chk2isoI-V5 dimer; ﬁlled
square, Xpress-Chk2wt/Chk2Δ4-V5 dimer.
Fig. 6. Chk2isoI forms stable homodimers and may interfere with Chk2wt homo-
dimerization. (A) Chk2isoI-V5 and Xpress-Chk2isoI were co-transfected into HCT116
(Chk2−/−) cells. After 48 h, the proteins were immunoprecipitated with anti-V5, and
the beads were washed with increasing NaCl concentration followed by immunoblot-
ting using anti-Xpress. (B) HCT116 (Chk2−/−) cells were triple transfected with
Xpress-Chk2isoI and V5- and Xpress-tagged Chk2wt. Cells were harvested after 48 h and
protein interaction was detected by pull-down experiments using anti-V5 and
immunoblotting with anti-Xpress.
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made by Xu and co workers [11], suggesting that Chk2 oligomeriza-
tion requires, at minimum, the presence of the FHA domain in
one Chk2 molecule and the SCD within the second Chk2 molecule. In
order to investigate the requirement of the FHA domain for dimer-
ization, a similar dimerization assay as presented in Fig. 5A was
performed by co-transfecting Xpress-Chk2isoI with Chk2isoI-V5 in
HCT116 (Chk2−/−) cells (Fig. 6A). Most intriguingly, this experi-
ment clearly shows the presence of a homodimer consisting of
Chk2isoI-V5 and Xpress-Chk2isoI, providing evidence that the FHA
domain is not absolutely required in either of the interacting
molecules for Chk2 oligomerization to take place.3.5. The Chk2 heterodimers are less stable than the Chk2 homodimers
The stability of the heterodimers was tested by repeating the
dimerization experiment as described in Fig. 5A followed by washing
with a buffer containing 0–1 M NaCl. Increasing the ionic strength of
the buffer destabilized the complexes as demonstrated in Fig. 5C. The
Chk2wt homodimer was clearly the most stable, but all heterodimers
were stable at 0.2 M NaCl. Thus, to achieve a 50% reduction in
heterodimerization, a NaCl concentration of 0.8 M was required. At a
NaCl concentration of 1 M, the amount of Chk2wt homodimer
complex was decreased to 80%, contrasting the heterodimer com-
plexes, for which 30–40% only remained stable at this concentration.
Interestingly, the removal of minor fragments of exon 4 (Chk2Δ4) and
exon 11 (Chk2Δ11) enhanced destabilization of the complexescomparable to that observed for the Chk2isoI and Chk2del(2-3)
forms, which lack larger parts of the protein.
Similarly, the stability of the V5-tagged and Xpress-tagged
Chk2isoI homodimer was tested in the presence of 0.3, 0.7 and
1.0 M NaCl (Fig. 6A). These data indicate the Chk2isoI homodimer to
be very stable, in fact, more stable than the Chk2wt-Chk2isoI
heterodimer (Fig. 5C). Taken together, the Chk2wt homodimer and
the Chk2isoI homodimer both appear to be more stable than the
Chk2wt-splice heterodimers.
3.6. The Chk2isoI splice variant may interfere with Chk2wt
homodimerization
In vivo, Chk2 molecules interact to form homodimers. Based on
this fact and the observation that Chk2wt formed a heterodimer with
Chk2isoI, we wanted to investigate whether or not Chk2isoI could
interfere with Chk2wt homodimerization. For this purpose, HCT116
(Chk2−/−) cells were transfected with Xpress-Chk2isoI, Xpress-
Chk2wt, and Chk2wt-V5. Fig. 6B shows the result of the immunopre-
cipitation using anti-V5 antibody. The pull-down experiment demon-
strates that both Xpress-tagged Chk2wt and Xpress-tagged Chk2isoI
were immunoprecipitated using anti-V5 antibody, indicating both
Chk2wt homodimers and Chk2wt-Chk2isoI heterodimers to be
present in the transfected cells. The amount of proteins in the cell
lysate prior to immunoprecipitation was semiquantitatively deter-
mined by western blot and Image Gauge 3.45. This analysis indicated
that the Xpress-Chk2isoI concentration was near 3-fold that of
392 E.O. Berge et al. / Biochimica et Biophysica Acta 1803 (2010) 386–395Xpress-Chk2wt (data not shown). However, the data presented in
Fig. 6B reveals that the Chk2wt-V5 bound Xpress-Chk2wt to a greater
extent than Xpress-Chk2isoI. This is in accordance with a higher
stability of the Chk2wt homodimer versus the Chk2wt-Chk2iosI
heterodimer, as shown in Fig. 5C. Nevertheless, the Chk2wt-Chk2isoI
heterodimer contributed substantially to the total dimer pool.
3.7. Chk2Δ4 has a higher kinetic speciﬁcity constant than Chk2wt
Chk2wt and splice variants were immunoprecipitated from
transfected U2-OS cells treated with or without doxorubicin, and
tested for autophosphorylation as well as kinase activity using
Cdc25C(200–256) as substrate (Fig. 4C and D). Doxorubicin treatment
only moderately increased the auto- and transphosphorylation levels
for Chk2Δ4, the other samples were not signiﬁcantly affected by the
DNA damage suggesting that complete activation can be obtained
through overexpression. Compared to Chk2wt, Chk2Δ4 showed a
higher level of auto- and transphosphorylation in cells exposed to
doxorubicin as well as in controls, while Chk2isoI and Chk2Δ11 both
were shown to be inactive with respect to kinase activity before as
well as after doxorubicin treatment. Chk2del(2-3) revealed only
minor changes in autophosphorylation after exposure to doxorubicin,
but a rather considerable decrease in the transphosphorylation
activity for both mock and doxorubicin treated samples.
For further characterization of the Chk2 splice forms, Km and Vmax
were determined by using the SigmaPlot Technical Graphing Software
(SPSS Inc.) and the Michaelis–Menten equation. The basic enzymatic
parameters for Chk2wt and splice variants using Cdc25C(200– 256) as
variable substrate is presented in Table 1. Consistent with structure
analysis data [32], Chk2isoI and Chk2Δ11 were kinase inactive. The
Chk2del(2-3) splice variant was slightly active, while Chk2Δ4 had a
Cdc25C(200– 256)-speciﬁc Km similar to that of Chk2wt. Most intrigu-
ingly, the Chk2Δ4 splice wasmore active than Chk2wt as demonstrated
by its higher speciﬁcity constant, Vmax/Km of 4471, compared to 1200
for Chk2wt.
3.8. The Chk2 splice variants attenuate the kinase activity of Chk2wt
The potential effect of the splice variants on Chk2wt enzyme
activity was studied in U2-OS cells co-transfected with Xpress-Chk2wt
and V5-tagged splice forms. After treatment with doxorubicin for
24 h, the lysates were immunoprecipitated with anti-V5 antibody.
The kinase activity of the various heterodimers was then measured
and normalized to the Xpress-Chk2wt levels. As shown in Fig. 7, the
kinase activity of Chk2wt was strongly reduced in the presence of
each of the different splice variants. Interestingly, this was the case
also for Chk2Δ4, despite the fact that this variant showed a higher
kinase activity than Chk2wt when measured separately.Fig. 7. Kinase activity of Chk2wt in heterodimer with Chk2 splice variants. Heterodimers
consisting of Xpress-Chk2wt and V5-tagged splice variants were pulled-down by anti-V5
from co-transfected and doxorubicin treated U2-OS cells followed by analysis of kinase
activity using Cdc25C(200–256) and γ-[32P]-ATP as substrate. The kinase activity of the
heterodimerswas calculated relative to the activity of the Chk2wt homodimerwhichwas
set to 100%. The experiment was repeated 3 times.4. Discussion
In the present work, we demonstrate that four different Chk2
splice variant proteins form heterodimers with wild-type Chk2 and
attenuate wild-type Chk2 kinase activity in vitro. These data provide
the ﬁrst indication that the large number of Chk2 splice variants that
exist in tumors [20] may play a role in down-regulating wild-type
Chk2 activity in malignancies. While somatic inactivation (mutations
and LOH) in Chk2 are rare in breast cancer [20,50,56,57] and con-
ﬂicting ﬁndings have been reported with respect to the role of
Chk2 in activating p53 [58], our previous [20,21] and current obser-
vations clearly imply the importance of Chk2 in response to DNA
damage agents in breast cancer, supporting a tumor suppressor role
for Chk2.
The ﬁrst indication of a role for Chk2 in carcinogenesis was
reported by Bell and colleagues in 1999 [33], suggesting germ line
alterations in Chk2 to be a cause of the Li–Fraumeni syndrome (LFS).
Subsequent studies [34–40] however did not ﬁnd any evidence
supporting a role of Chk2 mutations in LF or LF-like syndromes.
However, the Chk2 del1100C variant, occurring at a frequency of
0.11–1.6% in European populations [41], has been shown to be
associated with a moderate ( 3–5 fold) but signiﬁcantly elevated risk
of breast cancer [42].A moderate increased risk of breast cancer has
also been suggested for other Chk2 founder mutations like I157T
(470T>C), IVS2 +1 G>A, del5395, and S428F [43–48]. Recently, we
reported Chk2 nonsense mutations to be associated with resistance to
anthracycline treatment in breast cancer patients, suggesting that
Chk2mutationsmay substitute for TP53mutations in this respect [21].
However, the incidence of somatic Chk2mutations in breast cancer is
low [20,21,49,50], and thus we speculate whether Chk2 could be
inactivated by other mechanisms as well. Based on our previous
ﬁndings of comprehensive alternative splicing of Chk2 in human
breast cancer tissue [20] and several reports in the literature of genes
with alternative splice variants having antagonistic effects on the
wild-type molecules [9,51–53], we hypothesize that splice variant
proteins of Chk2 may express antagonistic activities toward the Chk2
wild-type protein.
First we found the half-lives of three of the Chk2 protein variants
to be similar to or slightly shorter than that of the Chk2wt protein,
while the half-life of the forth variant was extended, possibly due to
reduced ﬂexibility and protease access. The fact that each of the four
Chk2 splice variants examined was stably translated despite lacking
different functional domains suggests Chk2 splice variants in general
to encode stable proteins. The ﬁnding that each of the Chk2 splice
variants localized in the nucleus is in agreement with the retention
of the nuclear localization signal [29], and a putative biological func-
tionwould be performed at this location, in line with what is observed
for Chk2wt.
Phosphorylation of T68 by ATM is considered an essential step
in the activation of Chk2 [10]. Previous data has suggested that
the FHA domain is crucial for ATM-mediated phosphorylation
[12], possibly by mediating the docking of Chk2 to ATM [54]. Sur-
prisingly, in our experiments doxorubicin induced an increase in the
T68 phosphorylation levels of both Chk2Δ11 and Chk2del(2-3), the
latter lacking the FHA domain. This result indicates that the FHA
domain may under some circumstances not be obligatory for T68
phosphorylation, consistent with the ﬁndings of others [31]. On the
other hand, the T68 phosporylation level did not increase for
Chk2isoI and Chk2Δ4 following doxorubicin treatment, indicating
that ATM-mediated phosphorylation of Chk2 could be dependent
on the kinase domain and exon 4. It is important to note that
the increase in the level of T68 phosphorylation for Chk2Δ11 and
Chk2del(2-3) following doxorubicin treatment did not automati-
cally result in increased kinase activity. This is in accordance with a
previous work [55] concluding that even though T68 phosphoryla-
tion might be necessary to initiate dimerization and activation, it
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activity.
Chk2 forms homodimers to become fully activated, and the
model proposed by Oliver and collaborators [32] suggests that phos-
phorylation of a Chk2 molecule at T68 by ATM facilitates binding
to the FHA domain in a second Chk2 molecule followed by kinase
domain dimerization (Fig. 8A). None of the tumors for which Chk2
splice variants were identiﬁed, lacked the wild-type transcript.
Thus, we aimed at identifying the effect of the presence of Chk2
splice variant proteins on wild-type Chk2. Interestingly, exogenous
expression revealed that all four Chk2 protein variants tested
retained the ability to bind and form heterodimers with tagged
Chk2wt (modeled in Fig. 8B), and for three of the splice forms
heterodimerization was conﬁrmed with untagged Chk2wt. This
implies that the splice variants may interfere with endogenous wild-
type homodimer formation. Furthermore, in the cell lysate contain-
ing exogenously expressed Chk2IsoI and two differently tagged
Chk2wt, the Chk2wt-Chk2iosI heterodimer was formed and con-
tributed substantially to the total dimer pool. Even though immu-
noprecipitation and protein blotting are semiquantitative methods
only, these data add support to our hypothesis that Chk2 splice
variants, exempliﬁed by Chk2iosI, may form stable heterodimers
with Chk2wt molecules and thus compete with the endogenous
wild-type homodimer formation.
In order to conﬁrm these ﬁndings, we transfected the Chk2 splice
variants into HCT116 cells expressing Chk2 endogenously. Unexpect-
edly, we did not observe heterodimerization in these experiments.
Most likely, this was due to a too low expression level of endogenous
Chk2 in HCT116. Alternatively, the stress induced during transfection
could have caused phosphorylation and dimerization of endogenous
Chk2, leaving no monomeric Chk2 available for dimerization with
the exogenously expressed proteins. This is in line with our previousFig. 8.Model of Chk2 dimerization and activation. (A) In response to DNA damage, ATM phos
of one Chk2 molecule then binds to the FHA domain in another Chk2 molecule. Subsequently
by autophosphorylation. Activated and phosphorylated Chk2 molecules might persist in dim
splice variants. Due to loss of fragments of various lengths, the interacting molecules in theobservations revealing that V5-tagged Chk2wt formed dimers with
Xpress-tagged Chk2wt only following co-transfection/translation,
and not when mixing lysates from cells transfected separately (not
shown). Futhermore, following transfection, we and others [13,31]
have observed Chk2 phosphorylation and dimerization in the absence
of DNA damage stimuli, suggesting that Chk2 is activated and
dimerizes rather easily.
As each of the splice variants dimerized with Chk2wt, apparently
none of the segments missing in the splice form proteins need to be
present in both of the interacting molecules for dimerization to take
place. Based on the dimerizationmodel postulated by Oliver et al. [32],
we suggest that in the heterodimers, only the FHA–SCD interaction is
formed, explaining the comparable destabilization despite removal of
fragments of different size and location in the splice forms (Fig. 8B). In
further support, Chk2wt homodimers and Chk2IsoI homodimers were
more stable than the Chk2wt-Chk2isoI heterodimer, the two former
having no mismatching structures. The ﬁnding that Chk2isoI formed
homodimers was intriguing, since this splice variant lacks both the
FHA domain and a large portion of the kinase domain. This suggests
the FHA domain to be redundant for dimer formation, thus
contrasting previous ﬁndings [11]. In addition, Chk2wt-Chk2 splice
heterodimer formation was not affected by the level of T68 phos-
phorylation and kinase activity, which varied extensively among the
splice variants.
According to our examination of the stability of the complexes, the
Chk2wt homodimer was clearly more stable than the Chk2 hetero-
dimers. While autophosphorylation of kinase active Chk2 has been
suggested to reduce the afﬁnity and prevent stable Chk2 dimerization
in somemodels [11,31], we observed stable homodimers of Chk2wt at
1 M NaCl, and neither T68 phosphorylation nor kinase activity
prevented Chk2wt from forming stable dimers, supported by previous
observations [55].phorylates T68 located within the SCD domain of Chk2. The phosphorylated SCD domain
, the kinase domains form dimers through exchange of the protruding T loops followed
ers or dissociate to monomers. (B) Model of the interaction between Chk2wt and Chk2
heterodimers are not properly aligned for full activation of the Chk2wt molecule.
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various splice forms, we observed that removal of eight amino acids
located between the FHA and the kinase domains (Chk2Δ4) generated
a Chk2 variant which expressed a higher kinase activity than Chk2wt.
The reason for this increased enzymatic activity in unknown, but it
may be linked to its higher stability (Fig. 2). As expected, deletions
affecting the kinase domain, which is the case for Chk2isoI and
Chk2Δ11, resulted in kinase-inactive splice variants both prior to, and
after doxorubicin treatment. During Chk2 dimerization, the ex-
changed T loops in the kinase domains pack into the hydrophobic
recess lined by the helices 405–423 and 435–442 of its partner [32]. In
Chk2Δ11 (missing aa 420–431), the cavity is probably distorted,
explaining how even the small deletion in this splice variant is
sufﬁcient to completely rupture kinase activity. It was important to
note that the absence of the FHA domain in Chk2del(2-3) leads to a
relative reduction in transphosphorylation activity compared with
autophosphorylation. This implies that the FHA domain is essential for
phosphorylation and activation of downstream substrates. The minor
reduction in autophosphorylation, which would be expected to be
dependent on dimerization, is consistent with our observation of FHA
being redundant for Chk2 oligomerization to take place.
As dimerization is a prerequisite for Chk2 enzyme activation, an
important question is what effect the splice variants may have on
Chk2 wild-type kinase activity. Most importantly, each heterodimer
complex, including dimerization between Chk2wt and the Chk2Δ4 for
which the kinase activity speciﬁcity constant (Vmax/Km) was
approximately four times that of Chk2wt when measured separately,
revealed a kinase activity below that of the Chk2wt homodimer. This
ﬁnding reveals that each of the splice variants investigated, despite
dissimilarities with respect to functional domainmissing and intrinsic
kinase activity, exerts a dominant-negative effect on Chk2wt kinase
activity through heterodimerization. This is in line with a previous
study making similar suggestions for the mutated I157T Chk2 variant
[43]. The Chk2 wild-type molecules could possible be trapped in an
inactive state or alternative conformation induced by the Chk2 splice
variants, impairing its availability and function. Additionally, the
splice variants might bind but not transfer the activating signal from
or to various upstream (ATM) or downstream factors (Cdc25A,
Cdc25C and p53), reducing the pool accessible for the functional Chk2
wild-type. Taken together, our results reveal new data about the
functional domains and shed light on the activation mechanisms of
Chk2, expanding our knowledge about the tumor suppressor.
About 70 of the >90 different Chk2 splice forms identiﬁed in
breast cancer tissue [20] presented loss of exons similar to the splice
variants analyzed in this study, strongly suggesting that the
observation of an antagonizing effect on Chk2wt made for the splice
variant proteins analyzed in this work may be applied to many
additional Chk2 splice variants as well. Consequently, combined the
various splice variants may contribute to physiological changes due to
the total accumulated negative interference with Chk2 wild-type
activity. Based on this, we suggest that an increase in the number and
complexity of splice variants may represent a novel mechanism for
negative regulation of the biological function of Chk2, thus represent-
ing an alternative to mutational inactivation.
Most interesting, expression of the analyzed Chk2 splice formswas
associated with a lack of response to doxorubicin (Supplementary
Tables 1 and 2) despite harboring wild-type TP53 and Chk2. While
further studies are warranted, we hypothesize that Chk2 splicing may
represent a novel mechanism for inactivation of Chk2 function,
potentially contributing to development of chemoresistance in breast
cancer, as an alternative to mutational inactivation of Chk2 and TP53.
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